Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

OBJECTIVES: To determine (i) correlates for etanercept (ETA) discontinuation after achieving an inactive disease and for the subsequent risk of flare and (ii) to analyze the effectiveness of ETA in the re-treatment after a disease flare. METHODS: Data from two ongoing prospective registries, BiKeR a...

Descripción completa

Detalles Bibliográficos
Autores principales: Klotsche, Jens, Klein, Ariane, Niewerth, Martina, Hoff, Paula, Windschall, Daniel, Foeldvari, Ivan, Haas, Johannes-Peter, Horneff, Gerd, Minden, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050932/
https://www.ncbi.nlm.nih.gov/pubmed/33863349
http://dx.doi.org/10.1186/s13075-021-02492-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050932/
https://www.ncbi.nlm.nih.gov/pubmed/33863349
http://dx.doi.org/10.1186/s13075-021-02492-0

Ejemplares similares